Amwell sees a light at the end of the tunnel while losses continue, as usual.

The American Medical Association (AMA) asks for more guardrails on AI mental health chatbots. In three letters sent to the House and Senate Artificial Intelligence Caucuses and the Congressional Digital Health Caucus, the AMA’s concern was around the emotional dependency on AI systems, the potential distortion of reality through prolonged interaction with chatbots. and the current lack of consistent safety protocols. They outlined several areas needing attention:

1. Greater transparency in ensuring that users clearly understand when they are interacting with an AI system rather than a human being. Chatbots should not present as a licensed clinician or a human being. [See our earlier article on Pennsylvania’s suit against Character.AI]
2. Clearer regulatory boundaries around how AI chatbots are used in mental healthcare, including diagnosis and treatment requiring oversight.
3. Requesting that lawmakers direct agencies to establish a risk-based framework that clarifies when AI tools qualify as medical devices.
4. Requiring developers to build safeguards, such as crisis-detection capabilities that can identify potential self-harm risk and direct users to appropriate resources and de-escalate harmful situations.
5. Ongoing safety monitoring, mandatory reporting of adverse events, and stricter standards for tools used by children and adolescents.
6. Limits on commercial influence, including restrictions or bans on advertising within mental health chatbots, and that chatbots aren’t ‘influenced’ by financial incentives.
7. Robust data protection standards, including: limits on the amount of data collected and stored, safeguards to prevent unauthorized access or sharing of sensitive information, and clear user consent for data use.

Stanford’s recent research confirmed some common knowledge–that LLMs behind the chatbots pose significant risks by providing inappropriate responses, introducing bias and perpetuating stigma, which can result in dangerous consequences. AMA release, Mobihealthnews

Medicare beneficiary study compares hospital at home outcomes with traditional in-patient stays–and finds some good results. The JAMA Open Network published paper found that in over 15,000 patients (hospital at home, 4,174; in-patient 11, 697), treatment via “hospital at home was associated with significantly lower in-hospital mortality and emergency department (ED) use within 30 days of index admission discharge, with no significant difference in hospital readmissions within 30 days of index admission discharge compared with traditional inpatient care.” The study concluded that may maintain the same or better short term outcomes depending on “appropriately selected patients” (not specified) and that “future studies should evaluate implementation and equity”. The vast majority of patients in the hospital at home sample (nearly 97%) were urban. Healthcare Dive, JAMA Open Network

Character.AI’s chatbots are available for use by the general public. It has over 20 million active users worldwide. Anyone can go on the Character.AI website and register for free; a paid version costs $9.99 per month which provides priority access. According to the PA Professional Conduct Investigator (PCI), after creating a free account and his own character, he searched on ‘psychiatry’ and found “Emilie”. He presented with symptoms corresponding to depression. “Emilie” offered to complete an assessment for him as ‘within her remit as a Doctor’. “Emilie” represented herself as a physician graduate of Imperial College London, licensed with the General Medical Counsel in the UK with a full registration and with a specialty in psychiatry. When asked, “she” said she was also licensed in PA. The number “she” gave the PCI, however, was invalid. 

The Medical Practice Act prohibits engaging in the unlawful practice of medicine and surgery or purport to do so. The complaint seeks to restrain Character.AI in presenting its characters as licensed medical professionals.  Press release,  “Complaint in Equity”

Character.AI’s response, from a spokesperson quoted in The Hill, was to not comment on the litigation, to state that the chatbots were for entertainment and role playing, claiming that “We have taken robust steps to make that clear, including prominent disclaimers in every chat to remind users that a Character is not a real person and that everything a Character says should be treated as fiction.” In another statement to Becker’s, “We also add robust disclaimers making it clear that users should not rely on characters for any type of professional advice. Character.AI prioritizes responsible product development and has robust internal reviews and red-teaming processes in place to assess relevant features.”

Unfortunately for Character.AI, there’s a trail of additional lawsuits from families saying that the chatbot ‘characters’ led their children to mental health problems, self-harm, and suicide along with other forms of abuse. Kentucky earlier this year filed its own lawsuit in that the characters allegedly “preyed on children and led them into self-harm.” 

Its valuation stands above $1 billion and according to Crunchbase, between seed and Series A (both 2023), it has raised $230 million to date from Andreessen Horowitz, SV Angel, Greycroft, Elad Gil, and A. Capital Ventures.

Perhaps the rabbit is being pulled from the top hat. Or it’s hungry.

Oracle is taking on $16 billion debt, this time largely funded by bond fund PIMCO. This funded a single data center campus in Saline Township, Michigan. Total financing announced in late April was $16.3 billion, anchored by PIMCO’s financing $10 billion of the bond tranche plus $2 billion in equity from Related Digital Infrastructure and Blackstone. It’s reported that this is the largest single-facility technology debt package ever assembled. PIMCO (Pacific Investment Management Company LLC)  is a bond fund, the largest of its type (active fixed-income), and a subsidiary of Allianz Global Investors. It stepped in because US banks refused for the reasons bulleted below.

What gives pause is the total debt picture that Oracle is taking on to develop data centers for clients–OpenAI primarily, but also Meta. 

• $72 billion in total debt to finance the Stargate joint venture in Michigan, Texas, Wisconsin, and New Mexico. Other reports have indicated over $100 billion [TTA 10 Mar].
• The PIMCO debt is structured as a 7.5% coupon with a 19.5-year maturity, with six years of interest-only payments followed by 13 years of amortization
• Oracle’s long-term debt load has risen nearly 66% since the start of 2025.  Yahoo Finance
• This is despite a BBB-negative credit outlook from S&P Global Ratings and Moody’s Baa2 Negative outlook (link), a major factor in why banks shied away from further financing.
• $553 billion in performance obligations with OpenAI 

TNW discusses in a deeper dive the debt structure and why PIMCO could make this bet where banks could not.  The question it raises is whether the furious pace of data center building is another cycle of overbuilding–and if it is, will it be absorbed in time? The ominous parallels: the 2000s building boom in an earlier iteration of data centers, the fiberoptic boom of the early 2000s that broke WorldCom, Global Crossing, Winstar, Corning, and 360Networks, cloud overbuilding that left Amazon Web Services with years of excess capacity (it helps to have a deep-pocketed and not all that transparent parent), and others. This Editor would also liken it to the early years of 1980s-90s airline deregulation (too many airlines, too much debt, too many seats) and about a decade in the cruise ship industry where too many cabins were chasing too few people. These took decades and multiple bankruptcies to settle.

The Project Jupiter New Mexico Stargate data center is turning into an experiment to reduce the environmental/power impact of AI data centers. The alternative energy source for the Doña Ana County data center will come from fuel cells developed by Bloom Energy. The fuel cells have up to 2.45 GW of installed capacity and will replace the usual gas turbines and diesel generators, consolidating power into one single microgrid. How big this ‘microgrid’ will be is not disclosed. The data center campus is being built by a development company, BorderPlex Digital Assets, which is promoting this site as a “Tier 1 industrial engine for New Mexico”. 

Fuel cells generate electricity without combustion through electrochemically combining hydrogen and oxygen, producing water, heat, and electricity. Versus conventional power sources, they reduce nitrogen oxides emissions by approximately 92% and use a “negligible” amount of water. However, the overall picture is not quite that rosy. Other reports indicated that overall greenhouse gases emitted by the data center even with the fuel cell microgrid are estimated at 10 million tons per year, representing ~30% savings over a conventionally powered 14 million tons per year, the latter more than the cities of Las Cruces and Albuquerque. While preliminary construction is taking place, Project Jupiter is still awaiting approval from the New Mexico Environment Department and faces several lawsuits from environmental activists. SourceNM,  Oracle release

A Federal contract to expand the Department of War’s AI capabilities across their classified cloud network. No value attached, and details are naturally on the QT and strictly Hush-Hush, but Oracle’s May Day announcement says in about three ways that the agreement is for advancing AI capabilities as part of the DOW’s AI Acceleration Strategy by “enabling new capabilities across its three core tenets: warfighting, intelligence, and enterprise operations”. (Whew!) From the release: “This agreement accelerates the transformation toward making the United States military an AI-first fighting force and strengthens warfighters’ ability to maintain decision superiority across all domains of warfare.” Oracle release

Also Yahoo Finance

In the Chutes department…remember the scandal around healthcare ad trackers back in 2022?

A Bloomberg-Feroot Security investigation published this week uncovered that nearly all of the 20 health insurance exchanges (HIX) set up by states and the District of Columbia as part of the ACA use ad trackers. Information included sex, citizenship, and race. In New York State, the HIX shared the pages applicants visited during enrollment with TikTok, Meta, Snap Inc. and LinkedIn. Even details about incarcerated family members was shared. Over 7 million Americans buy health insurance through the state sites.

The problem is that Federal protections on personal information (personal health information–PHI, and personally identifiable information–PII) do not apply at the state level. State laws are inconsistent and incomplete. There are consumer protection laws, but again application is inconsistent. And rather neatly, the ad companies contractually place the compliance responsibility on advertisers. While ad trackers serve useful marketing and operational purposes for site analytics, data retention, and ad targeting, sending PHI and PII to third parties for that purpose violates privacy. 

The other 30 states use the Federal Healthcare.gov insurance exchange site. California removed trackers in 2025.

In 2022, ad trackers were on health system websites, large provider groups such as VillageMD, and e-prescribers such as the controversial Cerebral. Trackers such as Meta Pixel were disclosing all sorts of protected information that violated HIPAA and privacy guidelines to third parties such as Facebook, Instagram, and Google–and monetized. Most health systems removed them and Cerebral was fined for this as well as other issues. TTA 16 April 2024, 17 June 2022, 21 June 2022

The US Navy is sailing with WHOOP and Talkspace. WHOOP, through MIT Lincoln Laboratory, has been awarded a contract to support the US Navy’s Command Readiness, Endurance, and Watchstanding (CREW) program. The CREW program’s objective is to improve operational readiness by reducing fatigue-related risk. WHOOP’s fitness and health monitoring wearable will be used to integrate physiological data into the CREW system architecture by monitoring sleep, recovery, and strain.

To gain the Navy contract, WHOOP waged a successful Federal procurement battle with fitness ring Oura, which was awarded a $96 million contract in 2024. WHOOP argued that the specifications were too narrowly written in specifying a ring wearable and that the contract was awarded to a foreign company (Oura is based in Finland, WHOOP in Boston).  Certainly they had the funds to wage war with the Department of War; WHOOP scored a whopping $575 million Series G last month for a $10.1 billion valuation. The value of WHOOP’s contract via MIT is undisclosed. Oura has other contracts for projects with the Department of War. Release, Mobihealthnews

Talkspace is expanding its existing virtual behavioral health therapy program with the Navy to 40,000 sailors and families based at 13 Navy installations. They will have access to the Talkspace Go self-paced app and other offerings through their TRICARE benefits. Talkspace offers virtual therapy for anxiety, social anxiety, depression, ADHD, bipolar disorder, OCD, insomnia, postpartum depression, panic disorder, gambling addiction, schizophrenia, eating disorders and more, including medication refills. The company was bought for $838 million in March by Universal Health Services (UHS), a diversified for-profit health services provider, with the closing expected by Q3  [TTA 12 March]. There is no disclosure of the value of the contract nor the length. Mobihealthnews, Release

In M&A, ICON plc’s subsidiary Symphony Health is being acquired by HealthVerity. Purchase price is not disclosed. Symphony is a major company in the data analytics and clinical intelligence field with a massive commercial data repository, built on analyzing millions of patient claims and transactions for outcomes. ICON claims it stores 14 petabytes of data, sourced from over 900,000 providers and over 305 million patients. Clinical research organization (CRO) ICON acquired Symphony, founded in 2012 from four earlier health data companies, when it purchased PRA Health Sciences, also a CRO, in 2021. It was operated by ICON as a US subsidiary. The stated goal is to unite Symphony’s commercial health data with HealthVerity’s data exchange and patient identity systems. The deal is expected to close later this month. Release, Mobihealthnews

Medical device company Nervonik announced an oversubscribed $52.5 million Series B funding round. Their peripheral nerve stimulation (PNS) neuromodulation technology is used in high-motion areas of the body for chronic pain treatment. The financing was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital, bringing their total funding to over $65 million. Their PNS integrates stimulation with advanced sensing to deliver more precise and personalized therapy. Nervonik completed a first human clinical trial of nerve stimulation for chronic pain in March 2025. Release, Mobihealthnews

Imaging AI is the Undiscovered–but Mapped Out–Country. Deep Learning (DL)-based AI models developed using medical imaging have substantial validation over more than a decade, and they are accelerating. There have been multiple validated studies using information from retinal scans as predictors of future medical conditions such as Parkinson’s, heart disease, stroke, and Alzheimer’s Disease. The retina is apparently a diagnostic gateway to nearly every organ; many studies have focused on it as scans are fairly routine. Other AI-assisted models have used deep learning to detect multiple health conditions: thymus, cardiovascular conditions, through mammography, colonoscopy, and importantly, detecting pancreatic and other cancers from computed tomography (CT) images done for other reasons. “Opportunistic AI” alone is being used in detection for a long list of health conditions. Dr. Topol’s point is that none of these new diagnostic methods have made it into standard practice, despite being used in other countries like China (PANDA) and with at least four companies developing uses for retinal AI to detect specific diseases.

Medical LLMs and Generative AI, on the other hand, are building what may be Castles In The Air.  Seemingly everyone is developing, funding, and selling a LLM-based chatbot, LLM-aided diagnosis, management, patient triage, and direct patient use. Unfortunately, they’re being sold without real, continuous evidence through rigorous studies over time. What studies there are, are generally simulations, small-scale studies, or individual case studies which need further real-world validation. The clinical trials, the infrastructure, and the monitoring for safety, effectiveness, and cost are simply not there yet, and it’s past time. (Raj Manrai quoted in Science). In addition, generative AI keeps changing making studies harder to track results over time. Dr. Topol’s conclusion: “In summary, there is very little evidence for LLMs benefiting patients or doctors for health outcomes.”

That is not to say, as Dr. Topol does, that AI won’t grow in usefulness in areas such as medical research and chart summaries, discharge instructions, translations, administrative work such as documentation of billing codes, clinical workflow, and insurance authorization. AI has already worked its way into RCM where no respectable company does not have an AI-enabled tool. The American Medical Association (AMA) study he cites indicates both current use and growing acceptance by physicians. (To this Editor, it resembles the telehealth usage graphs of a decade ago, and she expects the same progress.) 

He calls it a paradox between imaging AI and LLMs. This Editor calls it a shame that healthcare technology and investment keep chasing what’s easy, ‘sexy’, and can generate fast revenue/ROI. Not what is more difficult but proven, and that can have a potential huge impact on health outcomes.

Dr. Topol’s closing is fitting:

Let’s fix this paradox of medical AI implementation. It’s a two-fold and major undertaking. Amping up the use of medical AI where it’s proven and performing the clinical trials required to justify wide-scale adoption where pivotal evidence is lacking.

ChatGPT moves from healthcare enterprises to the clinician level. This new version of OpenAI’s ChatGPT, ChatGPT for Clinicians, is designed to support clinical tasks like clinical search, documentation workflows, and deep medical research. It will be free for any verified physician, NP, PA, or pharmacist in the US, and is available now via their information page here. With its release, ChatGPT is also introducing HealthBench Professional, described as “an open benchmark for real clinician chat tasks across three use cases: care consult, writing and documentation, and medical research.” Release

ChatGPT for Healthcare was announced in January, but available to only a limited group of healthcare organizations.

UnitedHealth Group is having some better days. Last week on their earnings call, they announced that all units exceeded Q1 expectations. Their Q1 adjusted earnings per share (EPS) of $7.23 was well ahead of expectations, with total revenues of $111.7 billion, up 2% versus Q1 2025. Q1 membership fell slightly to 49.1 million from 49.8 million at the end of 2025. Their medical cost ratio (MCR) decreased to 83.9% from 84.8%, nearly a full point.

UHG is ‘on track’ to invest $1.5 billion in AI this year, especially at Optum with self-service digital scheduling that includes AI-enabled tools guiding patients “to the right appointment in the right setting at the right time”, plus increased digital access for members and providers with AI-enabled tools at UnitedHealth Care. 

UHG has been heavily criticized for its treatment of rural healthcare providers and hospitals. Timothy Noel, CEO of UnitedHealthcare Business, said that “We will accelerate payments in all lines of business by 50% for rural hospitals and exempt rural healthcare providers for most medical prior authorization requirements. And we are building network partnerships between rural providers and leading regional health systems.”  Let’s see if the good news stretches into Q2. Healthcare Finance News

Aidoc’s $150 million Series E brings their total funding to over $500 million. The AI-assisted clinical imaging system for radiology, cardiology, vascular and neurovascular healthcare teams is designed to help them find and triage injuries and other health conditions. It also integrates coordination software for stroke and cardiovascular care. The round for the NYC-based company was led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Investment Advisors and NVentures (NVIDIA’s venture capital arm). The fresh funds will be used to grow global presence and expand into other clinical areas. FDA clearance for its AI triage tool was gained in January. Mobihealthnews, Release 

TriFetch has a healthy pre-seed round. A $1.9 million pre-seed these days is rather unusual but TriFetch, an AI automation platform built for independent specialty clinics just emerging from stealth, nabbed it from Nexus Venture Partners, with participation from angels with backgrounds at Google, Hippocratic, Mercor, and MIT. TriFetch’s platform automates three workflows that dominate clinic operating costs (the “tri”): patient calls and scheduling, referral processing, and prior authorizations. It’s led by UCLA graduate computer science PhDs  and researchers Varuni Sarwal and Rosemary He. So far results seem impressive, with their pilots at California ophthalmology, cardiology, and gastroenterology clinics with results that save time and money. In one GI practice, with staff processing up to 100 referrals per day, TriFetch handled that workflow end to end, freeing roughly 16 hours of staff time daily, saving the clinic $200,000 per year.  Pulse 2.0/release

And for those who fetch for us, a diagnostic for heart murmurs. Boehringer Ingelheim, the German pharmaceutical company with a specialty in animal health, and Eko Health, a ‘reimagined’ stethoscope for heart and lung disease, partnered to develop a device and app to detect, visualize, and grade heart murmurs in dogs. This combines BI’s CANINEBEAT AI diagnostic algorithm, the Eko Vet+ app, and the Eko CORE Digital Attachment that connects to most single-tube stethoscopes.  Canine heart murmurs and cardiac disease are difficult to detect in early stages, where diagnosis and treatment can be most helpful. Availability of the combined technology through both BI and Eko has started in the US and UK, with Germany up next month. Additional markets will be phased in during 2026 and 2027.  Release 

The hottest doctor reference source withdrew its medical evidence and decision support app from the UK and European markets.

The screen at left (courtesy of HIStalk) cites the ‘regulatory uncertainty regarding the treatment of AI systems’ and invites potential users to ‘make their voice heard’.

OpenEvidence is perceived by most to be the ‘up and coming’ platform for physician information. Its momentum was solidified with deals such as with Mount Sinai NY to integrate it within Epic [TTA 9 Apr], a $250 million Series D funding, and a monster valuation of $12 billion, making it the most valuable healthcare AI company in this solar system. It couples a free search engine trained on journals and clinical medical data only with an AI chatbot agent, making it easy to use for doctors. OpenEvidence partners with prestigious sources such as the New England Journal of Medicine and the American Medical Association.  It claims a daily average usage by 40% of US doctors in 10,000 hospitals and medical centers, achieving 18 million clinical consults in December alone. It recently added clinical trial matching to its capabilities, filtering trials by study design, enrollment status, and geographic proximity. To the US industry, OpenEvidence fills a gap in clinical intelligence that competitors Doximity (public), Epocrates (athenahealth), and Medscape (WebMD) have not to date, which certainly hurts the latter as tight pharma ad dollars reroute to OpenEvidence, as TTA has previously noted. 

The EU and UK constraint will likely not hurt OpenEvidence’s growth, but will hurt physicians in those countries by blocking a reliable source of information. It hits the NHS where it hurts, in its desires for technology advancement and integrating AI in practices. DistilledPost has a more UK-specific discussion of the consequences. Meanwhile, this Editor doubts that OpenEvidence will let this sit, and will eventually find a way towards compliance while growing outside of those markets, such as the Middle East and Asia. They have the resources, the name, and the growth. Hat tip to HIStalk. Letsdatascience, 

The criminal hacker organization taking credit for it is the interestingly named ShinyHunters (what, not Shiny Stockings?) which claims it exfiltrated 9 million patient records with personally identifiable information (PII), 38 million records in total, as well as “terabytes” of internal corporate data. This immediately contradicts Medtronic’s anodyne corporate statement. However, the leak is no longer published on their dedicated leak website, according to Cybernews reported in TechRadar, which may indicate that some negotiations are going on. We’ll see if Medtronic will be changing their statement.

ShinyHunters is indulging in some chest beating, bragging on its leak website that they’ve stolen data from primarily consumer companies such as Zara, Carnival, 7-Eleven, Pitney Bowes, The Canada Life Assurance Company, and Hallmark. 

This fits a pattern of major healthcare hacking. Orthopedic medical device and robotics company Stryker was caught in a massive breach, wiping tens of thousands of systems and servers across the company’s network including applications such as Intune Company Portal, Teams, and VPN clients often used on personal devices. The perpetrator, Handala, is “linked to Iran’s Ministry of Intelligence and Security (MOIS) that targets Israeli organizations with destructive malware designed to wipe Windows and Linux devices.” This makes it political as a primary reason, economic secondary. [TTA 20 Mar]

Corporate IT is more vulnerable than production or patient-facing systems, according to Ensar Seker, chief information security officer at threat intelligence platform SOCRadar, quoted in MedCityNews. Corporate systems have high-value data but are less rigorously segmented and protected. MedTechDive

Another breach with international repercussions is that of UK Biobank. UK Biobank is a non-profit research database with information on 500,000 British citizens who volunteered their history and data. That data was found for sale on three separate listings on the Chinese e-commerce website Alibaba. Apparently no entity purchased the data. Unusually, the Chinese government assisted in the listings’ removal. (See below for the embarrassing reason why.)

Last Thursday (23 April), science minister Ian Murray told the House of Commons that the charity had informed the government about the data breach last Monday and thanked the Chinese government for assisting with the removal from Alibaba. Biobank has referred itself to the Information Commissioner’s Office. The hacker is not identified.

Dame Chi Onwurah, the Labor chair of the science, innovation and technology committee, scored her own Government, saying that it was “another blow to public confidence”, adding that it showed “little progress had been made” in protecting public data. Mr. Murray had assured her back in February that standards of public sector information security and data hygiene would improve.

The subjects joined the study over four years, 2006-2010, and at that time were between 40 and 69 years old. The information could include gender, age, month and year of birth, socioeconomic status, lifestyle habits, and measures from biological samples. The deidentified  information did not include names, addresses or contact details but what was included–genome sequences, hospital diagnoses, and biological measures–could be cross referenced and re-identified in experts’ view.

According to the Independent (via Yahoo UK), UK Biobank is the world’s most comprehensive dataset of biological, health and lifestyle information. It is used internationally and has been used to achieve improvements in the detection and treatment of dementia, cancers and Parkinson’s. DataBreaches.net

Update: the breach was apparently an Inside Job. The data was leaked dozens of times via GitHub. Three Chinese research institutions with legitimate access violated their data-sharing agreements. FTA: “It was not a hack. It was a contract violation by trusted researchers, and that distinction makes it worse, not better, because it exposes a vulnerability that no firewall can fix: the entire model of open research data sharing assumes that everyone who receives the data will follow the rules.” TheNextWeb

Being the cynical marketer and writer I am, I expected something more salesy, more commercial, more pitchy. This mercifully was not. It was informative. It used actor and endorser Jeremy Renner, plus testimonies from emergency service dispatchers and first responders, in a professional, low-key, and semi-documentary fashion. It was a video with real production values, increasingly a rarity. Not selling their AI assisted platform–the name wasn’t even mentioned–but in the circumstances of what public safety is, the people, what they do, and what they face, such as responding to emergencies in the rural backcountry of Nevada. Time is everything. It was about the problems they face and what emergency services need to be more effective. 

Why Mr. Renner? He was in a horrible accident in a snowcat three years in that backcountry, and became interested in emergency response as a result. While the benefit was clear–tech cuts the time for 911 public safety centers’ dispatchers and responders to coordinate multiple resources needed to respond to a call, and RapidSOS has the AI tech to connect the pieces more seamlessly and faster–it didn’t bang you over the head with The Brand or The Product even at the end. It may have been a 12 minute commercial, but it was a damn good one and a rare one today. You can view it here.

I also stuck around for part of the live panel that was with the CEO, Reno’s mayor Hillary Scheive, Reno’s director of public safety Cody Shadle, retired firefighter and founder of eFireX Jesse Corletto, and chaired by a company executive whose name I did not catch. It was again about the emergencies they typically face in both the city, the pressure on dispatchers in handling multiple situations, and more rural environments in Washoe County and how coordinating their resources over a large area is a huge challenge. Every connection made better saves time and is “good AI”. Drones, for instance, can get to a scene faster and feed data back to dispatchers as they coordinate, and responders as they are arriving.

A company that is beneficially using AI for the public, and an interesting, low-key exposition on how one company is integrating it into its services.

Editor’s note 1 May: Of interest to marketers re strategy is that the preview clip (on the website) is also being run as a RapidSOS commercial on streaming service Pluto. The spot closes with the logo and a link on a black screen. I suspect there are buys elsewhere.

Mr. Miller has drawn out 10 factors from the success, then failure of four companies: Olive AI, IBM Watson Health, Carbon Health, and Babylon Health–this last, one that TTA chronicled as far back as 2014, through the palmy Matt Hancock days, their questionable SPAC, and right to their near-complete dissolution. Back in February, we featured his article analyzing the Carbon Health failure. But all four have been profiled in impressive deep dives, available for subscribers on his Substack account. He does feature extensive free material and definitely is worth the follow.

This is not a long cuppa but very much worth your time and pondering. All This Has Happened Before